Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 44: 1417-1422, 1998;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (14)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Davelaar, E. M.
Right arrow Articles by Kenemans, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Davelaar, E. M.
Right arrow Articles by Kenemans, P.
Related Collections
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 1998;44:1417-1422.)
© 1998 American Association for Clinical Chemistry, Inc.

Enzymes and Protein Markers

Comparison of seven immunoassays for the quantification of CA 125 antigen in serum

Elvira M. Davelaar1, Gerard J. van Kamp2, Rob A. Verstraeten1, and Peter Kenemans1,a

Departments of
1 Obstetrics and Gynaecology, and
2 Clinical Chemistry, Academic Hospital Vrije Universiteit, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
a Author for correspondence. Fax 31-20-4444811; e-mail kenemans{at}azvu.nl.

Seven CA 125 immunoassays were compared for their clinical performance. CA 125 concentrations were determined in 289 serum samples obtained from women with benign pelvic tumors (samples from 98 patients) and patients with various cancers (samples from 111 patients). In the range of 0–1000 kilounits/L, all assays tested were linearly correlated, with correlation coefficients ranging from 0.89 to 0.99. In relation to the original Centocor CA 125 assay, there was an overall tendency to measure higher absolute values in the lower CA 125 value range. This was not seen in relation to the Centocor CA 125 II assay. ROC curves (benign vs pretreatment ovarian cancer patients) were nearly identical for all assays, and the areas under the ROC curves were not markedly different. We conclude that the CA 125 assays tested are strongly related to each other and are clinically reliable for the quantification of serum CA 125 and that none of the assays offers higher diagnostic accuracy or better discrimination between patient groups, especially not in the lower ranges.




The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
C. M. Sturgeon, M. J. Duffy, U.-H. Stenman, H. Lilja, N. Brunner, D. W. Chan, R. Babaian, R. C. Bast Jr., B. Dowell, F. J. Esteva, et al.
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers
Clin. Chem., December 1, 2008; 54(12): e11 - e79.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Santillan, R. Garg, M. L. Zahurak, G. J. Gardner, R. L. Giuntoli II, D. K. Armstrong, and R. E. Bristow
Risk of Epithelial Ovarian Cancer Recurrence in Patients With Rising Serum CA-125 Levels Within the Normal Range
J. Clin. Oncol., December 20, 2005; 23(36): 9338 - 9343.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. J. S. Rustin, R. C. Bast Jr., G. J. Kelloff, J. C. Barrett, S. K. Carter, P. D. Nisen, C. C. Sigman, D. R. Parkinson, and R. W. Ruddon
Use of CA-125 in Clinical Trial Evaluation of New Therapeutic Drugs for Ovarian Cancer
Clin. Cancer Res., June 1, 2004; 10(11): 3919 - 3926.
[Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
M. W. McIntosh, N. Urban, and B. Karlan
Generating Longitudinal Screening Algorithms Using Novel Biomarkers for Disease
Cancer Epidemiol. Biomarkers Prev., February 1, 2002; 11(2): 159 - 166.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
D. K. Pauler, U. Menon, M. McIntosh, H. L. Symecko, S. J. Skates, and I. J. Jacobs
Factors Influencing Serum CA125II Levels in Healthy Postmenopausal Women
Cancer Epidemiol. Biomarkers Prev., May 1, 2001; 10(5): 489 - 493.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the American Association for Clinical Chemistry.